Sales decline as demand for hepatitis C drugs peaks
First written in FY2017-Q2. 9 of 12 entries say "Restated". Latest entry: FY2022.
0 other companies' latest entry also says "Dropped".
- FY2022DroppedAnnual reportNo standalone disclosure of the risk that demand for hepatitis C treatments would reach maturity was identified in this fiscal year's Business and Other Risks or in the key risks to operating performance.
- FY2021-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in business or other risks relating to the market impact of fluctuations in demand for hepatitis C treatments. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in business or other risks relating to the market impact of fluctuations in demand for hepatitis C treatments. - FY2020-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in business or other risks relating to the market impact of fluctuations in demand for hepatitis C treatments. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in business or other risks relating to the market impact of fluctuations in demand for hepatitis C treatments. - FY2019-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in business or other risks relating to the market impact of fluctuations in demand for hepatitis C treatments. - FY2019-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no material change in business or other risks relating to the market impact of declining demand for hepatitis C treatments. - FY2018RestatedAnnual report
「Sales of prescription pharmaceuticals and related products remained firm amid a flat market affected by the promotion of generic drug use and declining demand for hepatitis C treatments.」
Declining demand for hepatitis C treatments continues to affect market conditions, but the market is described as flat, as in the previous quarter. - FY2018-Q3RestatedAnnual report
「Sales of prescription pharmaceuticals remained firm amid a flat market affected by the promotion of generic drug use and declining demand for hepatitis C treatments.」
Declining demand for hepatitis C treatments continues to be cited as a factor in market conditions, but the market is described as flat after negative growth in the previous quarter. - FY2018-Q2RestatedAnnual report
「Sales of prescription pharmaceuticals and related products remained at approximately the same level as the same period of the previous fiscal year, amid negative market growth caused by the promotion of generic drug use and declining demand for hepatitis C treatments.」
Declining demand for hepatitis C treatments continues to be cited as a factor behind negative market growth, but no further deterioration from the previous quarter is specifically indicated. - FY2017-Q3WorsenedAnnual report
「The market contracted due to the drug price cut implemented in April 2016 and the peaking of demand for hepatitis C treatments, among other factors, and conditions remained challenging.」
The maturity of demand for hepatitis C treatments was cited not only as a factor behind declining sales of individual products but also as a factor behind negative market growth. - FY2017-Q2First statedAnnual report
「Decline in sales as demand for hepatitis C treatments, which expanded last year, reached maturity」
For hepatitis C treatments, for which demand expanded in the previous year, the decline in sales as demand reached maturity was identified as an actual factor affecting performance.